Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytoma

Abstract

(68)Ga-DOTANOC PET/CT shows high diagnostic accuracy in patients with suspicion of pheochromocytoma and is superior to (131)I-MIBG imaging for this purpose. Best results of (68)Ga-DOTANOC PET/CT are seen in patients with MEN2-associated and malignant pheochromocytoma.

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

“…Change of any tumour volume and characteristics from the baseline may alter subsequent therapeutic approach. In sum, the significant higher diagnostic performance of 68 Ga-DOTATATE PET/ CT, on a per-lesion basis, in comparison with [14,16,26,33]. Whereas, the sensitivity of 18 F-FDG is rather similar on a per-patient basis (90.9 % vs 86-88 %) but is significantly lower on per-lesion basis (51.3 % vs 74 %) [14,16].…”

“…Although the diagnostic yield of 68 Ga-DOTA-peptides PET/CT in the detection of PCC/ PGL has been evaluated in several studies [23][24][25][26], its promising role in these tumours is still not largely accepted.…”

Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

“…In a small series of 12 patients with metastatic disease, GaTate helped detect significantly more lesions with substantially higher tumor-to-background contrast than did 123 I-MIBG (35). More recently, in a study of 62 patients with clinically suspected pheochromocytoma, GaNoc PET/CT had a sensitivity, specificity, and accuracy of 92%, 85%, and 90%, respectively, with 100% accuracy in 14 patients with multiple endocrine neoplasia type 2 (36). Its lesion-based accuracy (91%) was vastly superior to that for MIBG (67%); however, 131 I-MIBG was used, which is inferior to 123 I-MIBG.…”

PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy

“…2). [7][8][9] Three major 68 Ga-DOTA peptides are currently available for imaging: 68 Ga-DOTA-Phe 1 -Tyr 3 Cellular and extracellular targets that can be used in diagnostic PET/computed tomography (CT) imaging for targeted therapy. These targets include cell surface receptors (CSR), receptor tyrosine kinase (RTK), intracellular hormonal receptors (HR), and angiogenesis targets (AT) on neo-blood vessels (BV).…”